• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance 0

Bristol-Myers Slips As Citi Says Pfizer Not Interested In Acquisition

By Kurt Osterberg · On April 12, 2018

Shares of Bristol-Myers Squibb (BMY) are slipping after Citi analyst Andrew Baum said Pfizer’s (PFE) CEO made it clear to him that the latter has no interest in acquiring the company in the absence of transformational data or a de-rating in the stock.

PFIZER ‘BACKS AWAY’: After meeting with Pfizer’s CEO, COO and CSO, Citi’s Baum told investors that the company’s chief executive made clear to him that Pfizer has no interest in Bristol-Myers in the absence of transformational data or a de-rating. Pfizer has high conviction in its current pipeline and believes that the return on investment is considerably higher than high risk transformational deals, particularly in the dynamic immuno-oncology space, the analyst pointed out. Baum also noted that he anticipates Pfizer to meaningfully increase its current share repurchase program from the current $5B-$6B per annum to offset the earnings per share dilution from higher anticipated research and development investment to monetize its current pipeline. Regarding AstraZeneca (AZN), Pfizer’s CEO told the analyst that revisiting it as an M&A target was “impossible” given the political sensitivities likely compounded by Brexit. The analyst reiterated a Sell rating on Pfizer shares and said he continues to prefer shares of Bristol-Myers, Merck (MRK) and Eli Lilly (LLY).

BRISTOL-MYERS TARGET LOWERED: In a separate research note, Citi’s Baum lowered his price target for Bristol-Myers to $70 from $78 as Pfizer backs away from a potential takeover. The analyst’s previous price target reflected a 65% probability of acquisition, most likely by Pfizer at $83, he noted. Nonetheless, Baum told investors that he views his newly-lowered target price as conservative given the absence of contribution from CHECKMATE-9LA in first line non-small cell lung cancer, which has the potential to define a new standard of care regardless of baseline PDL1 and TMB tumor status. The analyst reiterated a Buy rating on Bristol-Myers shares.

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    The Benefits of Starting a Home-Based Business

  • Finance

    Rising IT Spend & Emerging Tech, Push CIO’s to Outsource More Software Development For 2021 and Beyond

  • Finance

    How to Leverage Your Limitations as a Business Owner and Turn Them Into Superpowers

No Comments

Leave a reply Cancel reply

Top Finance

  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce
  • Shark Tank Recap: Shed Defender, Tata Towels and Sanaia Applesauce Secure Deals Shark Tank Recap: Shed Defender, Tata Towels and Sanaia Applesauce Secure Deals
  • Hedge Funds In The US Hedge Funds In The US
  • One Ring To Rule Them All One Ring To Rule Them All
  • Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates

New Posts

  • The Benefits of Starting a Home-Based Business

    The Benefits of Starting a Home-Based Business

    January 20, 2021
  • Rising IT Spend & Emerging Tech, Push CIO’s to Outsource More Software Development For 2021 and Beyond

    Rising IT Spend & Emerging Tech, Push CIO’s to Outsource More Software Development For 2021 and Beyond

    January 20, 2021
  • How to Leverage Your Limitations as a Business Owner and Turn Them Into Superpowers

    How to Leverage Your Limitations as a Business Owner and Turn Them Into Superpowers

    January 20, 2021
  • Think Smart, Work Smarter: So You’ve Hired an Assistant or Want to…Now What?

    Think Smart, Work Smarter: So You’ve Hired an Assistant or Want to…Now What?

    January 20, 2021
  • Breaking Down Barriers — How Traditional Company Divisions Are a Thing of the Past

    Breaking Down Barriers — How Traditional Company Divisions Are a Thing of the Past

    January 19, 2021
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018 NJCEE. All Rights Reserved.